ATE231553T1 - Adrenomedullin - Google Patents

Adrenomedullin

Info

Publication number
ATE231553T1
ATE231553T1 AT94302948T AT94302948T ATE231553T1 AT E231553 T1 ATE231553 T1 AT E231553T1 AT 94302948 T AT94302948 T AT 94302948T AT 94302948 T AT94302948 T AT 94302948T AT E231553 T1 ATE231553 T1 AT E231553T1
Authority
AT
Austria
Prior art keywords
proam
proadrenomedullin
peptide
adrenomedullin
peptides
Prior art date
Application number
AT94302948T
Other languages
English (en)
Inventor
Kazuo Kitamura
Kenji Kangawa
Hisayuki Matsuo
Tanenao Eto
Original Assignee
Shionogi & Co
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Kenji Kangawa filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE231553T1 publication Critical patent/ATE231553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT94302948T 1993-04-26 1994-04-25 Adrenomedullin ATE231553T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9985693 1993-04-26
JP18310793 1993-07-23
JP29873693 1993-11-29
JP6079035A JP2774769B2 (ja) 1993-04-26 1994-04-18 アドレノメデュリン

Publications (1)

Publication Number Publication Date
ATE231553T1 true ATE231553T1 (de) 2003-02-15

Family

ID=27466245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94302948T ATE231553T1 (de) 1993-04-26 1994-04-25 Adrenomedullin

Country Status (9)

Country Link
US (4) US5639855A (de)
EP (1) EP0622458B1 (de)
JP (1) JP2774769B2 (de)
KR (1) KR100312443B1 (de)
AT (1) ATE231553T1 (de)
CA (1) CA2122112C (de)
DE (1) DE69432033T2 (de)
DK (1) DK0622458T3 (de)
ES (1) ES2191674T3 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114044824A (zh) * 2011-11-16 2022-02-15 艾德里诺医药公司 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512087A (ja) 1995-08-18 1999-10-19 アメリカ合衆国 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
JP2001524454A (ja) 1997-09-26 2001-12-04 オークランド ユニサーヴィスィズ リミテッド 治療方法
US6852692B1 (en) 1999-06-23 2005-02-08 Shionogi & Co., Ltd. Composition for promoting passive extension of bladder smooth muscle
WO2000078339A1 (fr) * 1999-06-23 2000-12-28 Shionogi & Co., Ltd. Inhibiteurs de contractions uterines
FR2821080B1 (fr) * 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
WO2003078460A1 (fr) * 2002-03-19 2003-09-25 Oncorex, Inc. Peptides, compositions medicinales contenant ce peptide et compositions medicinales anticancereuses
CA2499852A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1545287B1 (de) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulierende verbindungen und anwendungsverfahren
WO2004043383A2 (en) * 2002-11-07 2004-05-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US20080249115A1 (en) * 2003-09-08 2008-10-09 The Government Of The United States Of America, As Non Peptide Agonists and Antagonists of Adrenomedullin and Gastric Releasing Peptide
US20060099608A1 (en) * 2004-03-29 2006-05-11 Medstar Research Institute Methods of diagnosing cardiovascular disease
WO2005097172A2 (en) * 2004-03-31 2005-10-20 North Shore-Long Island Jewish Research Institute Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1844158A4 (de) * 2004-12-06 2010-09-08 Univ Johns Hopkins Biomarker für entzündliche darmerkrankung
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2006095711A1 (ja) * 2005-03-07 2006-09-14 Japan As Represented By General Director Of Agency Of National Cardiovascular Center アドレノメデュリンを用いて障害組織を再生または修復する方法
JP4505640B2 (ja) * 2005-04-12 2010-07-21 国立大学法人 宮崎大学 心筋障害の予防又は治療剤
WO2006112390A1 (ja) * 2005-04-14 2006-10-26 Japan As Represented By General Director Of Agency Of National Cardiovascular Center 脂肪由来前駆細胞およびその利用
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
WO2009104248A1 (ja) 2008-02-19 2009-08-27 国立大学法人旭川医科大学 アドレノメデュリン産生増強剤
WO2012096411A1 (ja) 2011-01-12 2012-07-19 国立大学法人宮崎大学 難治性炎症性腸疾患の予防又は治療方法
ES2387240B2 (es) * 2011-01-31 2013-04-26 Fundación Rioja Salud Péptido capaz de aumentar la velocidad de desplazamiento de una kinesina o su homóloga funcional sobre microtúbulos.
DK2780370T3 (da) * 2011-11-16 2019-10-28 Adrenomed Ag Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-ikke-ig skelet til anvendelse i terapi af en akut sygdom eller akut tilstand af en patient til at stabilisere kredsløbet
PL3553084T3 (pl) 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
LT2780371T (lt) * 2011-11-16 2019-05-27 Adrenomed Ag Adrenomeduliną (adm) atpažįstantis antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne ig struktūros karkasas, skirti paciento, sergančio lėtine arba ūmia liga, skysčių pusiausvyros reguliavimui
WO2013072510A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
US11067586B2 (en) 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
EP2780717B1 (de) 2011-11-16 2016-12-21 sphingotec GmbH Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
JP6259905B2 (ja) 2013-03-20 2018-01-10 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 血圧降下治療をガイドするアドレノメジュリン
WO2015141819A1 (ja) 2014-03-20 2015-09-24 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JP2018500272A (ja) * 2014-09-26 2018-01-11 バイエル ファーマ アクチエンゲゼルシャフト 安定化アドレノメデュリン誘導体およびその使用
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
SG11201900133WA (en) 2016-07-08 2019-02-27 Sphingotec Gmbh Adrenomedullin for assessing congestion in a subject with acute heart failure
EP3339324A1 (de) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
US20200299372A1 (en) 2016-12-16 2020-09-24 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP3604538A4 (de) 2017-03-29 2020-12-30 University of Miyazaki Adrenomedullinderivat mit langzeitwirkung
EP3438668A1 (de) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnose und risikostratifizierung von pilzinfektionen
CN111480076A (zh) 2017-10-18 2020-07-31 艾德里诺医药公司 抗肾上腺髓质素（adm）结合剂治疗下的疗法监测
EP3502706A1 (de) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin
BR112020014940A2 (pt) 2018-02-08 2020-12-08 Sphingotec Gmbh Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência
EP3715851A1 (de) 2019-03-29 2020-09-30 B.R.A.H.M.S GmbH Verschreibung von fernpatientenmanagement auf der basis von biomarkern
WO2020201078A1 (en) 2019-03-29 2020-10-08 B.R.A.H.M.S Gmbh Prescription of remote patient management based on biomarkers
EP3871689A1 (de) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
JP2023516615A (ja) 2020-02-27 2023-04-20 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３
CN115244080A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
MX2022011581A (es) 2020-03-16 2022-10-18 Adrenomed Ag Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina.
US20230174607A1 (en) 2020-04-02 2023-06-08 University Of Miyazaki Novel Adrenomedullin Analog, Method for Producing the Same, and Pharmaceutical Use Thereof
EP4023218A1 (de) 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
CA3218162A1 (en) 2021-05-07 2022-11-10 Deborah BERGMANN Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) * 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPH04282399A (ja) * 1991-03-08 1992-10-07 Fujisawa Pharmaceut Co Ltd 放射性ヨウ素標識インシュリン様成長因子ｉ
ATE284413T1 (de) * 1993-08-09 2004-12-15 Sod Conseils Rech Applic Therapeutische peptid derivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114044824A (zh) * 2011-11-16 2022-02-15 艾德里诺医药公司 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架

Also Published As

Publication number Publication date
AU678212B2 (en) 1997-05-22
US5837823A (en) 1998-11-17
DE69432033D1 (de) 2003-02-27
DE69432033T2 (de) 2003-09-25
JPH07196693A (ja) 1995-08-01
DK0622458T3 (da) 2003-05-19
US5639855A (en) 1997-06-17
EP0622458B1 (de) 2003-01-22
US5830703A (en) 1998-11-03
KR100312443B1 (ko) 2002-02-28
CA2122112A1 (en) 1994-10-27
EP0622458A2 (de) 1994-11-02
EP0622458A3 (en) 1996-06-12
ES2191674T3 (es) 2003-09-16
AU6064894A (en) 1994-10-27
JP2774769B2 (ja) 1998-07-09
US5910416A (en) 1999-06-08
CA2122112C (en) 1999-02-16

Similar Documents

Publication Publication Date Title
ATE231553T1 (de) Adrenomedullin
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
DK150992A (da) Fremgangsmaade til fremstilling af et polypeptidfragment af faktor viii:c, dna-sekvens og ekstrachromosomalt element indeholdende en saadan dna-sekvens, som koder herfor
ATE105867T1 (de) Immunaffinitäts-reinigungssystem.
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
IE841734L (en) Modified protease inhibitors
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
DK1336109T3 (da) Kit og fremgangsmåde til at påvise proteinet EMS-1
KR900700500A (ko) 재조합 유전자 기술에 의한 에라스타제 억제 폴리펩티드 제조방법 및 에라스타제 억제 폴리펩티드
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
ES8606411A1 (es) Procedimiento para la determinacion de fibrina
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
ATE190318T1 (de) Pcna bindende substanz
GB9816514D0 (en) Novel method
EP1117682A4 (de) Peptide
DK450187D0 (da) Fremgangsmaade til fremstilling af proteiner
FI942392A0 (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
MELOUN et al. Acidic acrosin inhibitors from bull seminal plasma. Structural differences
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
ES504996A0 (es) Un procedimiento para aislar un polipeptido purificado
AR033043A1 (es) Proteina del tipo reg

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0622458

Country of ref document: EP